Cargando…
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential
Chimeric antigen receptor (CAR)-engineered T (CAR-T) cells have obtained prominent achievement in the clinical immunotherapy of hematological malignant tumors, leading to a rapid development of cellular immunotherapy in cancer treatment. Scientists are also aware of the prospective advantages of CAR...
Autores principales: | Wang, Xiao, Yang, Xuejiao, Yuan, Xiang, Wang, Wenbo, Wang, Yueying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628181/ https://www.ncbi.nlm.nih.gov/pubmed/36324149 http://dx.doi.org/10.1186/s40164-022-00341-7 |
Ejemplares similares
-
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
por: Lee, Maxwell Y, et al.
Publicado: (2021) -
Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors
por: Kim, Nayoung, et al.
Publicado: (2021) -
Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer
por: Cartellieri, Marc, et al.
Publicado: (2010) -
Combination of Expanded Allogeneic NK Cells and T Cell-Based Immunotherapy Exert Enhanced Antitumor Effects
por: Wang, Xiao, et al.
Publicado: (2022) -
Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges
por: Han, Ethan Q, et al.
Publicado: (2013)